These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10183698)

  • 21. [Secondary liver involvement in multiple myeloma: diagnostic imaging with magnetic resonance tomography (MRI)].
    Ajaj W; Yang F; Ruehm SG
    Rofo; 2003 May; 175(5):706-7. PubMed ID: 12743867
    [No Abstract]   [Full Text] [Related]  

  • 22. Severe anaphylactoid reaction to Gd-DTPA.
    Lufkin RB
    Radiology; 1990 Sep; 176(3):879. PubMed ID: 2389057
    [No Abstract]   [Full Text] [Related]  

  • 23. Diffusion-perfusion in intra-axial brain tumors with high relaxivity contrast agents.
    Cotton F
    Neuroradiology; 2006 Apr; 48 Suppl 1():34-40. PubMed ID: 16699850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
    Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
    J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.
    Idée JM; Port M; Raynal I; Schaefer M; Le Greneur S; Corot C
    Fundam Clin Pharmacol; 2006 Dec; 20(6):563-76. PubMed ID: 17109649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of brain metastases by magnetic resonance imaging: which magnetic resonance imaging sequence works best?
    Tikkakoski T
    Acta Radiol; 2008 Dec; 49(10):1097-8. PubMed ID: 18941952
    [No Abstract]   [Full Text] [Related]  

  • 27. Investigation of MR contrast media utility with the VX-2 tumor model.
    Runge VM; Williams NM
    Acad Radiol; 1998 Apr; 5 Suppl 1():S34-6; discussion S45-6. PubMed ID: 9561038
    [No Abstract]   [Full Text] [Related]  

  • 28. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications.
    Essig M; Weber MA; von Tengg-Kobligk H; Knopp MV; Yuh WT; Giesel FL
    Top Magn Reson Imaging; 2006 Apr; 17(2):89-106. PubMed ID: 17198225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.
    Caravan P
    Chem Soc Rev; 2006 Jun; 35(6):512-23. PubMed ID: 16729145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A mannitol solution as an oral contrast medium in pelvic MRT].
    Schunk K; Kersjes W; Schadmand-Fischer S; Grebe P; Kauczor HU; Thelen M
    Rofo; 1995 Jul; 163(1):60-6. PubMed ID: 7626755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adverse reactions to contrast media for magnetic resonance and echography].
    Simonetti G; Fanucci E; Masala S
    Radiol Med; 2004 Apr; 107(4 Suppl 1):34-5. PubMed ID: 15323320
    [No Abstract]   [Full Text] [Related]  

  • 33. Synthesis and evaluation of gadolinium complexes based on PAMAM as MRI contrast agents.
    Yan GP; Hu B; Liu ML; Li LY
    J Pharm Pharmacol; 2005 Mar; 57(3):351-7. PubMed ID: 15807991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.
    Giesel FL; Mehndiratta A; Risse F; Rius M; Zechmann CM; von Tengg-Kobligk H; Gerigk L; Kauczor HU; Politi M; Essig M; Griffiths PD; Wilkinson ID
    Acta Radiol; 2009 Jun; 50(5):521-30. PubMed ID: 19337867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNS imaging of neoplasms.
    Bragg DG; Osborn AG
    Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):841-5. PubMed ID: 1869474
    [No Abstract]   [Full Text] [Related]  

  • 37. Gadolinium-induced nephrotoxicity.
    Buhaescu I; Izzedine H
    Int J Clin Pract; 2008 Jul; 62(7):1113-8. PubMed ID: 18218006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging.
    Alric C; Taleb J; Le Duc G; Mandon C; Billotey C; Le Meur-Herland A; Brochard T; Vocanson F; Janier M; Perriat P; Roux S; Tillement O
    J Am Chem Soc; 2008 May; 130(18):5908-15. PubMed ID: 18407638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
    Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
    Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early detection of perfusion deficits caused by regional cerebral ischemia in cats. T2-weighted magnetic susceptibility MRI using a nonionic dysprosium contrast agent.
    Rocklage SM; Moseley ME; Kucharczyk J; Norman D; Quay SC
    Invest Radiol; 1990 Sep; 25 Suppl 1():S37-8. PubMed ID: 2283250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.